The World Health Organisation (WHO) has published its global cholera statistics for 2024, showing an increase in both the number of people who fell sick and died from the disease.
In a statement yesterday, it reported that cholera cases rose by five per cent and deaths by 50 per cent in 2024 compared to 2023, with more than 6,000 people dying from a disease that is both preventable and treatable.
”While these numbers are themselves alarming, they are underestimates of the true burden of cholera. Conflict, climate change, population displacement, and long-term deficiencies in water, sanitation, and hygiene infrastructure continue to fuel the rise of cholera.
”A disease caused by the bacterium, Vibrio cholerae, spreads rapidly through faeces-contaminated water,” it said.
The statement said 60 countries reported cases in 2024, an increase from 45 in 2023.
”The burden of the disease remained concentrated in Africa, the Middle East, and Asia, which collectively accounted for 98 per cent of all reported cases,” it said.
It said the scope of cholera outbreaks continued to expand in 2024, with 12 countries each reporting more than 10,000 cases, seven of which experiencing large outbreaks for the first time in the year.
The statement said the resurgence of cholera in Comoros -after more than 15 years without reported outbreaks underscored the persistent threat of global transmission.
It said the case fatality ratio for Africa increased from 1.4 per cent in 2023 to 1.9 per cent in 2024, revealing critical gaps in the delivery of life-saving care.
The WHO said it signaled the fragility of many health systems, along with challenges in access to basic health services.
”One quarter of deaths occurred in the community, outside of health facilities, highlighting serious gaps in access to treatment and the need to strengthen work with communities.
”To combat cholera, governments, donors and communities need to ensure people have access to safe water and hygiene facilities, have accurate information on how to protect themselves, and rapid access to treatment and vaccination when there are outbreaks.
”Strong surveillance and diagnostics will help guide these responses.
“Further investment in vaccine production is also needed,” it said.
The statement said that a new, innovative Oral Cholera Vaccine (OCV), Euvichol-S®, was prequalified in early 2024 and entered the global stockpile. (NAN)
